PharmGKB: The Pharmacogenomics Knowledge Base

Gene:
SLC2A9
solute carrier family 2 (facilitated glucose transporter), member 9

Overview

Alternate Names: SLC2A9 GLUT9; human glucose transporter-like protein-9; solute carrier family 2, member 9 protein; urate voltage-driven efflux transporter 1
Alternate Symbols: GLUT9; GLUTX; Glut9; UAQTL2; URATv1
PharmGKB Accession Id: PA37771

Details

Cytogenetic Location: chr4 : p16.1
GP mRNA Boundary†: chr4 : 9436946 - 9650970
GP Gene Boundary†: chr4 : 9433946 - 9660970
Strand: minus
Product Name: human glucose transporter-like protein-9, solute carrier family 2 (facilitated glucose transporter), member 9, solute carrier family 2, member 9 protein, solute carrier family 2, member 9 protein isoform 1, solute carrier family 2, member 9 protein isoform 2
† The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Curated Annotations (Curated Annotation)

  1. rs2018643 at chr4:9556219 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  2. rs4621431 at chr4:9556688 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  3. rs4339211 at chr4:9556756 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00002. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  4. rs7686538 at chr4:9557175 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00007. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  5. rs4580649 at chr4:9557559 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  6. rs12498150 at chr4:9559635 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  7. rs12498956 at chr4:9559803 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  8. rs13328050 at chr4:9560218 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00006. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  9. rs1079128 at chr4:9560319 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  10. rs9993410 at chr4:9560362 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  11. rs4455410 at chr4:9562395 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  12. rs9994266 at chr4:9563548 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  13. rs7376948 at chr4:9563806 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  14. rs7378305 at chr4:9563991 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  15. rs7378340 at chr4:9564296 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  16. rs4519796 at chr4:9565034 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00007. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  17. rs4311316 at chr4:9565069 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  18. rs4314284 at chr4:9565194 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  19. rs4312757 at chr4:9565243 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  20. rs6814664 at chr4:9565326 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00008. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  21. rs6449155 at chr4:9565645 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  22. rs17185835 at chr4:9567278 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  23. rs17185870 at chr4:9567312 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  24. rs6815001 at chr4:9567760 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00009. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  25. rs6849729 at chr4:9567830 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  26. rs6843873 at chr4:9567886 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00009. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  27. rs6844316 at chr4:9568075 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  28. rs6834893 at chr4:9568221 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00006. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  29. rs6449157 at chr4:9569540 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  30. rs6449159 at chr4:9569596 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  31. rs7672947 at chr4:9570466 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  32. rs6823361 at chr4:9572225 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  33. rs6836706 at chr4:9573349 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  34. rs10018204 at chr4:9573668 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. In combination, rs10018204, rs11222869, rs16965867, rs1846644, and rs6539870 were significant predictors of etoposide IC50, accounting for 55% of the etoposide IC50 variation in Caucasians. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  35. rs6839490 at chr4:9574098 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  36. rs6449171 at chr4:9575096 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  37. rs6449172 at chr4:9575134 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  38. rs6449174 at chr4:9575520 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  39. rs7658170 at chr4:9575691 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  40. rs7676733 at chr4:9576054 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  41. rs10017674 at chr4:9576151 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  42. rs7435196 at chr4:9576654 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00005. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  43. rs6449176 at chr4:9576941 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  44. rs6449178 at chr4:9577782 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  45. rs6449179 at chr4:9578215 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  46. rs7677710 at chr4:9578615 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  47. rs4473653 at chr4:9580156 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00008. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  48. rs13103879 at chr4:9581977 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00009. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  49. rs6852441 at chr4:9582842 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913
  50. rs6449201 at chr4:9582992 in SLC2A9
    Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00003. Type of association: FA; GN.
    Related Drugs:
    etoposide
    Related Diseases:
    Drug Toxicity
    Evidence:
    PMID:17537913

Non-Curated Annotations (Non-Curated Annotation)

  1. rs16890979 at chr4:9531265 in SLC2A9
    GWAS results: Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. (Initial Sample Size: 11,847 individuals; Replication Sample Size: 14,867 individuals); (Region: 4p16.1; Reported Gene(s): SLC2A9; Risk Allele: rs16890979-T); (p-value= 0).This variant is associated with Serum urate.
    Evidence:
    PMID:18834626
    http://www.genome.gov/gwastudies/
  2. rs13129697 at chr4:9536065 in SLC2A9
    GWAS results: Genome-wide association study of biochemical traits in Korcula Island, Croatia. (Initial Sample Size: 898 individuals; Replication Sample Size: NR); (Region: 4p16.1; Reported Gene(s): SLC2A9; Risk Allele: rs13129697-C); (p-value= 0.000000001).This variant is associated with Biochemical measures.
    Evidence:
    PMID:19260141
    http://www.genome.gov/gwastudies/
  3. rs737267 at chr4:9543842 in SLC2A9
    GWAS Results: SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout (Initial Sample Size: 794 individuals; Replication Sample Size: 706 individuals; Risk Allele: rs737267-C).
    Related Diseases:
    Cardiovascular Diseases
    Evidence:
    PMID:18327257
    http://www.genome.gov/gwastudies/
  4. rs6855911 at chr4:9545008 in SLC2A9
    GWAS Results: The GLUT9 Gene Is Associated with Serum Uric Acid Levels in Sardinia and Chianti Cohorts (Initial Sample Size: 4,305 Sardinian individuals; Replication Sample Size: 1,301 Tuscan individuals; Risk Allele: rs6855911-A). This variant is associated with serum urate levels.
    Related Diseases:
    Cardiovascular Diseases
    Evidence:
    PMID:17997608
    http://www.genome.gov/gwastudies/
  5. rs7442295 at chr4:9575478 in SLC2A9
    GWAS Results: Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia (Initial Sample Size: 1,955 hypertensive individuals; Replication Sample Size: 2,033 individuals in 519 families; 1,461 twins (1/pair selected randomly); Risk Allele: rs7442295-A). This variant is associated with serum urate levels.
    Related Diseases:
    Cardiovascular Diseases, Coronary Disease
    Evidence:
    PMID:18179892
    http://www.genome.gov/gwastudies/
  6. rs7442295 at chr4:9575478 in SLC2A9
    GWAS Results: SLC2A9 influences uric acid concentrations with pronounced sex-specific effects (Initial Sample Size: 1,644 individuals; Replication Sample Size: 9,947 individuals; Risk Allele: rs7442295-C).
    Related Diseases:
    Cardiovascular Diseases
    Evidence:
    PMID:18327256
    http://www.genome.gov/gwastudies/
Variant names are different names that have been used in the literature and other resources to refer to the same variant. Non-curated variant information is accumulated solely by computational methods and has not been verified by the scientific staff at PharmGKB.

Curated Information

The following diseases are in curated knowledge about this gene.

  Disease Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
Gout
  •   
  •   
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Hypouricemia
  • CO
  •   
  •   
  • FA
  • GN
Publications

Non-Curated Information

A list of non-curated publications that mention this gene along with other diseases is available.

LinkOuts

Entrez Gene ID:
56606
OMIM Accession:
606142
612076
UCSC Genome Browser ID:
NM_020041
Ref Seq NM Accession:
NM_001001290
NM_020041
Ref Seq NP Accession:
AAF85942
AAH18897
AAI10415
AAL16939
AAY41052
ABM82868
ABM86055
EAW92681
EAW92682
EAW92683
NP_001001290
NP_064425
Q9NRM0
Ref Seq NT Accession:
AC_000047
AC_000136
NC_000004
NG_011540
NT_006316
NW_001838900
NW_922073
UniProtKB Accesssion:
GTR9_HUMAN (Q9NRM0)
Ensembl ID:
ENSG00000109667
GenAtlas ID:
SLC2A9
GeneCard ID:
SLC2A9
SOURCE ID:
SLC2A9
MutDB ID:
SLC2A9
PromoLign ID:
ortho_2199
HuGE ID:
SLC2A9
Comparative Toxicogenomics Acc ID:
56606
ModBase:
Q9NRM0

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (GM61374).
©2001-2010 PharmGKB.